fbpx
Screen-Shot-2019-08-03-at-12.37.51-AM

Avenue Therapeutics, an 18-month 168% upside target

Betting on a potential FDA approval is a high-risk game. Without insider information, it is near impossible to accurately guess the probabilities of an approval. There are special occasions though in which we are given information that might give us that extra bit of confidence, and this is the case with Avenue Therapeutics (ATXI). The …

Avenue Therapeutics, an 18-month 168% upside target Read More »

To access this post, you must purchase The Alpha Advisory.
Scroll to Top